DNA X, Inc.
SONM
$4.75
$0.010.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -52.95% | -24.31% | 4.17% | -16.41% | -31.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.95% | -24.31% | 4.17% | -16.41% | -31.16% |
| Cost of Revenue | 9.71% | -32.08% | -44.69% | -62.20% | -66.11% |
| Gross Profit | -33.21% | -61.36% | -77.84% | -62.05% | -77.93% |
| SG&A Expenses | 799.91% | 74.39% | -101.99% | -100.79% | -106.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 152.62% | 74.39% | -118.36% | -119.69% | -117.79% |
| Operating Income | -536.53% | -74.39% | 75.39% | 84.14% | 48.94% |
| Income Before Tax | -927.47% | -175.93% | 68.59% | 81.79% | 62.53% |
| Income Tax Expenses | 48.70% | -17.92% | -38.44% | -27.07% | -60.10% |
| Earnings from Continuing Operations | -1,064.39% | -175.93% | 69.84% | 82.63% | 70.90% |
| Earnings from Discontinued Operations | -371.53% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.21% | 38.61% | -149.38% | -200.96% | -839.62% |
| EBIT | -536.53% | -74.39% | 75.39% | 84.14% | 48.94% |
| EBITDA | -256.43% | -342.01% | 106.17% | 131.01% | 4,556.36% |
| EPS Basic | 79.75% | 79.03% | -91.04% | -156.51% | -790.93% |
| Normalized Basic EPS | -283.78% | 7.16% | 127.62% | 125.11% | 76.15% |
| EPS Diluted | 79.74% | 79.02% | -91.12% | -156.28% | -773.76% |
| Normalized Diluted EPS | -283.78% | 7.16% | 127.62% | 125.06% | 76.56% |
| Average Basic Shares Outstanding | 213.66% | 146.57% | 105.56% | 39.66% | 15.61% |
| Average Diluted Shares Outstanding | 213.66% | 146.57% | 105.56% | 38.78% | 13.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |